Back to Authors

Stingl, Julia

https://orcid.org/0000-0002-1566-8156

A5080262638 | I123859907

Mayo Clinic

Federal Institute for Drugs and Medical Devices

Citations 1

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

Clinical Pharmacology & Therapeutics | May 13, 2015 | Volume: 98 | Issue: 2 | Pages: 127-134

10.1002/cpt.147 | PMID 25974703

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org ).